In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead

Prof. Adrian Hill, the Jenner Institute’s director, in Oxford.
Mary Turner for The New York Times

Date Published: April 27, 2020

Source: The New York Times

Scientists at the University of Oxford’s Jenner Institute have begun human clinical trials to study the safety and effectiveness of a new vaccine against COVID-19. Due to the researchers’ experience in creating vaccines against other viruses including MERS and Ebola, regulators have allowed them to start a Phase I trial of 1,100 individuals last week, with the hope of continuing to Phase II and Phase III trials involving another 5,000 individuals next month. So far their vaccine has shown potential immunity in rhesus macaque monkeys, which are a species closely related to humans and have been used for vaccine testing. This research group is also consulting manufacturing companies across Europe and Asia, so that if the vaccine is shown to be safe and effective, millions of doses could potentially be ready by September. Other companies worldwide have also begun clinical trials, including Moderna and Inovio in the United States and SinoVac in China.

Read the full article here:

Summary by: Helen Genis